Claims

1.-23. (cancelled)

24. (currently amended) A method for the treatment of <u>a</u> viral infection in a subject in need thereof, comprising administering <u>to the subject in need of treatment for the viral infection</u>, <u>in an effective amount effective to treat the viral infection</u>, an aniline derivative represented by the following formula (I):

$$R^4$$
 R^1
 Q
 R^3
 W
 R^2

(I)

or a pharmaceutically acceptable salt or hydrate thereof;

wherein, R^1 represents a hydrogen atom, a C_{1-6} alkyl group which may have a substituent, a C_{2-6} alkenyl group which may have a substituent, a C_{2-6} alkynyl group which may have a substituent, a C_{6-10} aryl group which may have a substituent, a halogen atom, a nitro group, a cyano group, an azide group, a hydroxy group, a C_{1-6} alkoxy group which may have a substituent, a C_{1-6} alkylsulfonyl group which may have a substituent, a carboxyl group, a formyl group, a C_{1-6} alkoxycarbonyl group which may have a substituent, an acyl group, an acylamino group, or a sulfamoyl group;

 R^2 represents a hydrogen atom, a C_{1-6} alkyl group which may have a substituent, or an aryl group which may have a substituent;

 R^3 represents a $C_{1.6}$ -alkyl group which may have a substituent, a $C_{2.6}$ -alkenyl group which may have a substituent, or a nitrogen-containing heterocycle which may have a substituent, or a condensed aromatic heterocycle which may have a substituent;

R⁴ represents a hydrogen atom or a halogen atom;

 $Q \ represents \ -C(O)-, \ -C(S)-, \ -SO_2-, \ -C(S)NHC(O)-, \ -C(O)NHC(O)-, \ or \ -C(O)NHC(S)-;$

W represents a hydrogen atom, a C_{1-6} alkyl group which may have a substituent, a C_{6-10} aryl group which may have a substituent, a halogen atom, a hydroxy group, a C_{1-6} alkoxy group which may have a substituent, a C_{1-6} alkylthio group which may have a substituent, a nitrogencontaining heterocycle which may have a substituent, a condensed aromatic heterocycle which may have a substituent, or a group represented by the following formula (II):

$$R^{5}$$
 R^{6}

wherein, R^5 and R^6 are the same or different and each represents a hydrogen atom, a C_{1-6} alkyl group which may have a substituent, a nitrogen-containing heterocycle which may have a substituent, a condensed aromatic heterocycle which may have a substituent, an acyl group, or an acylamino group;

(II)

the above R⁵ and R⁶ together with the adjacent nitrogen atom may form a heterocycle which may have a substituent, and the heterocycle may be a condensed aromatic heterocycle which may have a substituent;

the above R⁵ and R⁶ may be a cycloalkylidene amino group which may have a substituent, or an aromatic condensed cycloalkylidene group which may have a substituent, thereby treating the viral infection in the subject.

25. (currently amended) The method of claim 24, wherein R¹ is a hydrogen atom, a C₁₋₆ alkyl group which may have a substituent, or a halogen atom;

R² is a hydrogen atom-or a C₁₋₆-alkyl group;

 R^3 is a C_{6-10} aryl group which may have a substituent, or a nitrogen-containing 5- to 10-membered heteroaryl group which may have a substituent;

R⁴ is a hydrogen atom-or a halogen atom;

Q represents -C(O)-, -C(S)-, -SO₂-, -C(S)NHC(O)-, -C(O)NHC(O)-, or -C(O)NHC(S)-;

W represents a hydrogen atom, a halogen atom, or a group represented by the following formula (II):

$$R^{5}$$
 R^{6}

(II)

wherein, R^5 and R^6 are the same or different and each represent a C_{1-6} alkyl group which may have a substituent; or

the above R⁵ and R⁶ together with the adjacent nitrogen atom may form a heterocyclic group which may have a substituent, and the heterocyclic group may be a condensed aromatic heterocyclic group which may have a substituent.

26. (previously presented) The method of claim 24, wherein the aniline derivative of formula (I) is represented by the following formula (III):

(III)

or a pharmaceutically acceptable salt or hydrate thereof; wherein, R¹ is a hydrogen atom, a fluorine atom or a trifluoromethyl group; W represents

Q represents -C(O)- or -C(S)-.

27. (currently amended) The method of claim 24, wherein the viral infection is caused by:

- (1) any one of the following RNA viruses: a human immunodeficiency virus (HPVHIV), severe acute respiratory syndrome (SARS), poliovirus, human rhinovirus, adult T cell leukemia virus HHTKHTLV-I), hepatitis A, C, D, and E viruses, vaccinia virus, Japanese encephalitis virus, dengue virus, human coronavirus, Ebola virus, influenza virus, or sindbis virus; or
- (2) any one of the following DNA viruses: a herpes simplex virus, human adenovirus, hepatitis B virus, cytomegalovirus, EB virus, herpesvirus, human herpesvirus, smallpox virus, polyoma virus, or human papilloma virus.
- 28. (currently amended) The method of claim 27, wherein the viral infection is caused by a human immunodeficiency virus (HPVHIV).
- 29. (previously presented) The method of claim 27, wherein the viral infection is caused by a herpes simplex virus.
- 30. (previously presented) The method of claim 27, wherein the viral infection is caused by a human adenovirus.
- 31. (previously presented) The method of claim 27, wherein the viral infection is caused by a cytomegalovirus.

Page 5 of 10